Clinical Phenotype and Contagiousness of Early Breakthrough SARS-CoV-2 Infections after BNT162b2 COVID-19 mRNA Vaccine: A Parallel Cohort Study in Healthcare Workers.
BNT162b2
COVID-19
clinical manifestations
contagiousness
cycle threshold
mRNA vaccines
protection
symptoms
vaccine
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
23 Nov 2021
23 Nov 2021
Historique:
received:
04
11
2021
revised:
19
11
2021
accepted:
20
11
2021
entrez:
28
12
2021
pubmed:
29
12
2021
medline:
29
12
2021
Statut:
epublish
Résumé
We evaluated the clinical protection of BNT162b2 mRNA vaccine in healthcare workers (HCWs) and how COVID-19 manifestations and contagiousness change as the time since first dose increases. A matched (1:2 ratio) parallel cohort study was performed. During the first three months of vaccination campaign, HCWs of the entire health district ASL Città di Torino (Turin, Italy) were classified according to SARS-CoV-2-positivity in respect of the vaccination schedule: post-first-dose (fHCWs, <12 days), partially (PHCWs, ≥12 from first dose to ≤7 days after the second), and totally vaccinated (THCWs, ≥8 days after the second dose). Age-/sex-matched unvaccinated controls were randomly selected from all the SARS-CoV-2-positivity detected in the same district and period. Previous infections were excluded. Clinical and virologic data (ORF1ab gene cycle threshold values, Ct) were recorded. In total, 6800 HCWs received at least one dose, and 55 tested positive subsequently: 20 fHCWs, 25 PHCWs, 10 THCWs. Furthermore, 21.8% of breakthrough infections were in male, with a median age of 49 years (32-56), and 51.4% occurred while SARS-CoV-2 B.1.1.7 variant was predominant. The incident relative risk was 0.13 (0.12-0.15) for PHCWs and 0.06 (0.05-0.07) for THCWs. Compared to controls (
Identifiants
pubmed: 34960123
pii: vaccines9121377
doi: 10.3390/vaccines9121377
pmc: PMC8705309
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Lancet Infect Dis. 2021 Jul;21(7):939-949
pubmed: 33930320
JAMA. 2021 Jun 22;325(24):2457-2465
pubmed: 33956048
Lancet Infect Dis. 2021 Oct 29;:
pubmed: 34756186
MMWR Morb Mortal Wkly Rep. 2021 Apr 02;70(13):495-500
pubmed: 33793460
Viruses. 2021 Feb 11;13(2):
pubmed: 33670360
Laryngoscope. 2020 Nov;130(11):2520-2525
pubmed: 32617983
Clin Infect Dis. 2021 Mar 10;:
pubmed: 33704435
Clin Infect Dis. 2021 Sep 15;73(6):e1365-e1367
pubmed: 33768222
JAMA Netw Open. 2021 Jun 1;4(6):e2115985
pubmed: 34097044
JAMA. 2021 Jun 22;325(24):2500-2502
pubmed: 33956050
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Lancet. 2021 Mar 6;397(10277):875-877
pubmed: 33610193
Infect Dis Ther. 2020 Sep;9(3):573-586
pubmed: 32725536
Neurology. 2021 Jan 12;96(2):e294-e300
pubmed: 33004602
Med (N Y). 2021 Jun 11;2(6):682-688.e4
pubmed: 33851143
N Engl J Med. 2021 Apr 15;384(15):1412-1423
pubmed: 33626250
N Engl J Med. 2021 May 6;384(18):1775-1777
pubmed: 33755373
Clin Infect Dis. 2021 Jun 17;:
pubmed: 34137815
J Infect. 2021 Jul;83(1):119-145
pubmed: 33852930
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
Clin Infect Dis. 2021 Dec 6;73(11):2147-2148
pubmed: 33825859
Nat Med. 2021 May;27(5):790-792
pubmed: 33782619
Clin Chim Acta. 2021 Aug;519:60-63
pubmed: 33857476
N Engl J Med. 2021 May 6;384(18):1774-1775
pubmed: 33755376
Inflammopharmacology. 2021 Oct;29(5):1357-1360
pubmed: 34279767
Virol J. 2021 Aug 14;18(1):168
pubmed: 34391446